Ameriprise Financial Inc Cor Medix Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $47,723 - $74,743	11,697 New	11,697 $50,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $38,520 - $47,722	10,700 New	10,700 $39,000
Q4 2022 Feb 14, 2023	SELL	$2.81 - $4.45 $27,257 - $43,165	-9,700 Reduced 35.27%	17,800 $75,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $1,785 - $4,760	-633 Reduced 2.25%	27,500 $78,000
Q2 2022 Aug 15, 2022	SELL	$2.73 - $5.61 $17,745 - $36,465	-6,500 Reduced 18.77%	28,133 $113,000
Q4 2021 Feb 14, 2022	SELL	$4.47 - $5.56 $67,885 - $84,439	-15,187 Reduced 30.48%	34,633 $158,000
Q3 2021 Nov 15, 2021	SELL	$4.46 - $7.11 $33,762 - $53,822	-7,570 Reduced 13.19%	49,820 $231,000
Q2 2021 Aug 16, 2021	BUY	$6.05 - $10.09 $19,329 - $32,237	3,195 Added 5.9%	57,390 $394,000
Q1 2021 May 17, 2021	BUY	$6.84 - $17.58 $224,386 - $576,711	32,805 Added 153.37%	54,195 $542,000
Q4 2020 Feb 12, 2021	BUY	$5.0 - $9.15 $106,950 - $195,718	21,390 New	21,390 $151,000

109

17.4M

134K

441K

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $502M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.